Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

The present study retrospectively analyzed the outcomes of 89 young patients with acquired severe aplastic anemia (SAA) who underwent unmanipulated alternative hematopoietic stem cell transplantation (HSCT) between September 2012 and September 2016 at our single center. Forty-one patients received haploidentical (haplo-) donors and 48 patients matched unrelated donors (MUDs) for HSCT. No significant differences were observed between haplo-HSCT and MUD HSCT cohorts in 3-year overall survival (P = .210), disease-free survival (P = .127), and graft-versus-host disease-free failure-free survival (P = .976). Haplo-HSCT, as salvage therapy, achieved similar outcomes as MUD HSCT in young SAA patients, thereby rendering it an effective and safe option for young SAA patients.